David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Perspectives in Biology and Medicine 54 (3):304-315 (2011)
In early 1984, the AIDS epidemic was less than four years old. Chemists at the pharmaceutical company Syntex, situated in the rolling green hills near Stanford University in Palo Alto, California, had recently synthesized a new antiviral drug (Martin et al. 1983). The drug, at first given the awkward chemical abbreviation DHPG, later came to be known by the generic name ganciclovir. Ganciclovir was a potent drug for the treatment of herpes virus infection (such as genital herpes or chickenpox), but the unique characteristic of ganciclovir was that it worked against cytomegalovirus (CMV), a heretofore untreatable virus infection. Although relatively harmless in healthy individuals, CMV caused ..
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Rinaldo B. Schinazi (2006). The Probability of Treatment Induced Drug Resistance. Acta Biotheoretica 54 (1):13-19.
Don C. Des Jarlais, Paul A. Gaist & Samuel R. Friedman (1995). Ethical Issues in Research on Preventing HIV Infection Among Injecting Drug Users. Science and Engineering Ethics 1 (2):133-144.
Matthias Adam (2005). Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry. Studies in History and Philosophy of Science Part C 36 (3):513-537.
Nancy F. Olivieri (2003). Patients' Health or Company Profits? The Commercialisation of Academic Research. Science and Engineering Ethics 9 (1):29-41.
Matthias Adam (2011). Multi-Level Complexities in Technological Development: Competing Strategies for Drug Discovery. In M. Carrier & A. Nordmann (eds.), Science in the Context of Application. Springer. 67--83.
Harvey E. Bale (2005). Industry, Innovation and Social Values. Science and Engineering Ethics 11 (1):31-40.
Susan Haack (2005). Scientific Secrecy and 'Spin': The Sad, Sleazy Saga of the Trials of Remune. Social Science Research Network.
Michael G. Tyshenko (2009). The Impact of Nanomedicine Development on North–South Equity and Equal Opportunities in Healthcare. Studies in Ethics, Law, and Technology 3 (3).
Laurence J. Hirsch (2002). Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc. Science and Engineering Ethics 8 (3):429-442.
Hugh LaFollette (1994). Mandatory Drug Testing. In S. Luper & C. Brown (eds.), Drugs, Morality, and the Law. Garland.
Micahel F. Green, Stimulating the Development of Drug Treatments to Improve Cognition in Schizophrenia.
Zbigniew Szawarski (2004). The Concept of Placebo. Science and Engineering Ethics 10 (1):57-64.
Added to index2011-08-19
Total downloads37 ( #66,703 of 1,696,600 )
Recent downloads (6 months)4 ( #144,274 of 1,696,600 )
How can I increase my downloads?